-This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with
STOCKHOLM, SWEDEN - August 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics